Matthew Nichols, MD
Gastroenterology · Lone Tree, CONPI 1952451379
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $293,509 of the $359,536 with a category attached, or 81.6%. AbbVie accounts for 68.8% of it on its own, with 34 other manufacturers making up the rest. 2025 is the largest year on record at $105,811, 5.6 times the $18,861 reported in 2019. Among gastroenterology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 907 payments — averaging $396.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$247K
- Lilly USA, LLC$63K
- Johnson & Johnson$39K
- Eli Lilly$5K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$648
- plus $3K from 29 others
Across 30 payments — averaging $1208.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$21K
- Gilead$16K
What the payments were for
- Consulting fees$20,0006%
- Speaking & faculty fees$293,50982%
- Travel & lodging$28,4358%
- Food & beverage$17,5205%
- Education$730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 452 | $247,445 |
| Lilly USA, LLC | 135 | $63,034 |
| Johnson & Johnson(2 entities) | 75 | $38,991 |
| Eli Lilly | 9 | $5,435 |
| Takeda Pharmaceuticals U.S.A., Inc. | 46 | $1,129 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 35 | $648 |
| Pfizer | 29 | $463 |
| Bristol Myers Squibb | 30 | $454 |
| QOL Medical, LLC | 11 | $199 |
| Ipsen Biopharmaceuticals, Inc | 3 | $176 |
| Sanofi | 7 | $169 |
| Gilead | 8 | $161 |
| Intercept Pharmaceuticals, Inc. | 10 | $148 |
| Regeneron Healthcare Solutions, Inc. | 7 | $139 |
| Ardelyx, Inc. | 5 | $124 |
| Ironwood Pharmaceuticals, Inc | 5 | $98 |
| Ferring Pharmaceuticals Inc. | 5 | $96 |
| Madrigal Pharmaceuticals | 4 | $92 |
| Braintree Laboratories, Inc. | 5 | $68 |
| Celltrion USA Inc. | 2 | $56 |
| Phathom Pharmaceuticals, Inc. | 3 | $48 |
| Daiichi Sankyo Inc. | 3 | $42 |
| Merck | 3 | $40 |
| Sirtex Medical Inc | 1 | $38 |
| Nestle Healthcare Nutrition Inc. | 2 | $36 |
| Conmed Corporation | 1 | $36 |
| Shire North American Group Inc | 2 | $33 |
| Alfasigma USA, Inc. | 2 | $26 |
| Boehringer Ingelheim | 1 | $24 |
| Amgen | 1 | $17 |
| Novo Nordisk | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Mylan Institutional Inc. | 1 | $15 |
| UCB, Inc. | 1 | $13 |
| Organon | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$359,536 in reported general payments places this provider in the 95th percentile of 304 gastroenterology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 37 | $1,076,775 |
| RinvoqUpadacitinib | 50 | $334,094 |
| CreonLipase/Protease/Amylase | 26 | $72,067 |
| LinzessLinaclotide | 17 | $20,386 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 101 | $16,521 |
| Mesalamine | 31 | $16,269 |
| MotegrityPrucalopride Succinate | 15 | $12,734 |
| Budesonide DrBudesonide | 57 | $10,416 |
| Dexlansoprazole DrDexlansoprazole | 27 | $9,477 |
| Mercaptopurine | 18 | $3,282 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 60 | $2,437 |
| Azathioprine | 15 | $2,285 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 17 | $2,156 |
| Pantoprazole Sodium | 149 | $1,792 |
| Omeprazole | 67 | $1,097 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $38,991 | $1,076,77537 claims |
| AbbVieRinvoq, Creon, Linzess | $247,445 | $426,54793 claims |
| Braintree Laboratories, Inc.Sutab, Suflave | $68 | $18,678118 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $1,129 | $12,73415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 304 gastroenterology providers in Colorado.
Other gastroenterology in Lone Tree
- Nathan SchomakerLone Tree$344K
- Blake NiccumLone Tree$15K
- Theresa LeeLone Tree$9K
- Peter McNallyFt Carson$1.1M
- Douglas AdlerColorado Springs$910K
- Marcelo KugelmasEnglewood$660K
- Mary Ann HuangDenver$408K
- Gareth WeinerThornton$382K
- Joshua SteinbergNorthglenn$266K
- Rajesh JainLakewood$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.